Selected data models

You must log in to select data models for download or further analysis.

14 Search results.
Relevance Rating New first Old first

Eligibility Acute Lymphoblastic Leukemia NCT02010931

- 12/21/15 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02010931

A Parallel Group Study of Fluticasone Furoate/Vilanterol in Subjects with Asthma - 106837 - Screen Failure Form

- 11/28/18 - 1 form, 1 itemgroup, 3 items, 1 language
Itemgroup: Screen Failure Data
Study ID: 106837 Clinical Study ID: HZA106837 Study Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01086384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Relvar Study Indication: Asthma

Eligibility Inflammatory Bowel Disease NCT01464151

- 8/31/18 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study; ODM derived from: https://clinicaltrials.gov/show/NCT01464151 Sponsor: UMC Utrecht Collaborators: Merck Sharp & Dohme Corp. Ferring Pharmaceuticals Information provided by (Responsible Party): B. Oldenburg, UMC Utrecht

Eligibility Thyroid Cancer, Papillary NCT01659385

- 8/26/18 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Leptin Levels in Papillary Thyroid Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01659385

Eligibility Acute Heart Failure NCT02350114

- 12/7/15 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
An Observational Study of the Functional Capacity of Heart Failure; ODM derived from: https://clinicaltrials.gov/show/NCT02350114

A Parallel Group Study of Fluticasone Furoate/Vilanterol in Subjects with Asthma - 106837 - Eligibility Form

- 11/26/18 - 1 form, 4 itemgroups, 29 items, 1 language
Itemgroups: Eligibility Question, Inclusion Criteria, Dosage Lists, Exclusion Criteria
Study ID: 106837 Clinical Study ID: HZA106837 Study Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01086384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Relvar Study Indication: Asthma

Immunogenicity of co-administration of Tritanrix™-HepB and DTPw-HBV vaccines or Triple Antigen™ and Engerix™-B with HRV vaccine to infants (3, 4½ and 6 month) - 104021 - Contraindications to Subsequent Vaccination

- 11/28/18 - 1 form, 9 itemgroups, 8 items, 1 language
Itemgroups: Absolute Contraindications, DTPw vaccines, GSK Biologicals' RotarixTM vaccine or its placebo, Local registered OPV, Relative Contraindications, DTPw vaccines, GSK Biologicals' RotarixTM or its placebo, Precautions for DTPw vaccines, DTPw-HBV vaccines should under no circumstances be administered intravenously
Study ID: 104021 Clinical Study ID: 104021 Study Title: A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158756 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: Engerix B Study Indication: Hepatitis B

Eligibility Ischemia NCT00661323

- 1/16/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluating a New Echocardiography Imaging Procedure for Evaluating Heart Function; ODM derived from: https://clinicaltrials.gov/show/NCT00661323

Eligibility Ischemia NCT00661323

- 1/16/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluating a New Echocardiography Imaging Procedure for Evaluating Heart Function; ODM derived from: https://clinicaltrials.gov/show/NCT00661323

Eligibility Thyroid and Breast Tumors NCT01668238

- 9/20/21 - 1 form, 3 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria, Healthy Volunteers Inclusion Criteria
Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry; ODM derived from: https://clinicaltrials.gov/show/NCT01668238 Sponsor: XU Zhi Collaborator: Peking University

Eligibility Rheumatoid Arthritis NCT01166620

- 6/23/21 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on Biologics; ODM derived from: https://clinicaltrials.gov/show/NCT01166620

Immunogenicity of co-administration of Tritanrix™-HepB and DTPw-HBV vaccines or Triple Antigen™ and Engerix™-B with HRV vaccine to infants (3, 4½ and 6 month) - 104021 - Elimination Criteria (Study Eligibility)

- 11/28/18 - 1 form, 1 itemgroup, 5 items, 1 language
Itemgroup: Elimination Criteria during the Study
Study ID: 104021 Clinical Study ID: 104021 Study Title: A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158756 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: Engerix B Study Indication: Hepatitis B

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial